The Virginia Department of Health (VDH) announced last week that a man from the New River health district in Southwest Virginia has died from Hantavirus disease.
The man died last week after being hospitalized for pneumonia. Laboratory tests were conducted at the Division of Consolidated Laboratory Services and the Centers for Disease Control and Prevention (CDC). VDH received confirmation of Hantavirus from CDC Wednesday afternoon. Only one other case of Hantavirus disease has been reported in Virginia in 1993.
Our sympathy goes out to this mans family and colleagues at such a difficult time, said state health commissioner, Robert B. Stroube, M.D., M.P.H. This is a very rare and unexpected event.
The man was a Virginia Tech student and had recently been conducting field studies of small mammals in West Virginia. Health officials believe that he was most likely exposed to the virus through contact with the urine, feces or saliva of these animals. Hantavirus disease is not transmitted from person to person and there does not appear to be an ongoing risk to public health.
Hantavirus pulmonary syndrome (HPS) disease is a rare but extremely serious illness of the lungs caused by a family of viruses known as Hantavirus. Persons who have exposure to wild rodents or rodent-infested areas are at highest risk of getting HPS. The virus, which is found in the animals urine, droppings and saliva, gets in the air as mist or dust when droppings or nests are stirred up and can be spread to humans who inhale the virus.
Hantavirus can also be transmitted by handling rodents or by touching your nose or mouth after handling contaminated materials. A rodents bite can also spread the virus. There is no evidence that cats, dogs, farm animals, or insects transmit the disease to humans. You cannot get HPS from another person.
The initial symptoms are fever (101 to 104 degrees F), fatigue, and muscle aches. Other common symptoms that may occur are headache, dizziness, chills, nausea, vomiting, diarrhea, and abdominal pain. Later symptoms of HPS are coughing and shortness of breath caused by fluid build-up in the lungs. These breathing problems start four to10 days after the first symptoms and can progress to respiratory failure and sometimes death. At the present time, there is no specific treatment for HPS.
Cases of Hantavirus disease are rare, but people should always take precautions when coming in contact with rodents, stressed Stroube.
Source: Virginia Department of Health
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
COVID-19 Realities: Beyond a Respiratory Virus, Addressing Optimism in Pandemic Management
February 28th 2024A recent commentary by Dr. Amesh Adalja in MedPage Today challenges the perception of COVID-19 as solely a respiratory virus, highlighting its broader impact on the body. This analysis questions the notion that COVID-19 should be managed like common respiratory infections, urging a closer look at vaccine effectiveness, the rise of long COVID, and the need for enhanced measures to curb the virus's spread. Let's explore the complexities of COVID-19 management and the pressing realities faced by the US and the world.